THE US Food and Drug Administration has approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes and cardiovascular disease.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Dec 16
